Merck &
3/10
Score changed by 2 points as of 2026-05-10. Driver-level breakdown unavailable for this change — likely because the company's reported financial concepts shifted between filings (e.g. a 10-Q omitting a tag the 10-K used) or the scoring methodology was updated. Compare the metrics table below against prior periods on EDGAR for context.
Merck & has $13.1B in scheduled debt maturities. Notably, the entire $13.1B maturity schedule falls within five years, creating a concentrated refinancing window. DebtCanary scores MRK at 3/10, suggesting manageable refinancing risk.
Maturity Schedule
| Period | Amount Due |
|---|---|
| Year 1 (0-12 months) | $2.6B |
| Year 2 (12-24 months) | $2.7B |
| Year 3 (24-36 months) | $2.1B |
| Year 4 (36-48 months) | $3.0B |
| Year 5 (48-60 months) | $2.7B |
| Beyond 5 Years | N/A |
| Total Scheduled Maturities | $13.1B |
Key Metrics
Score Components
| Component | Value |
|---|---|
| Near-Term Maturity Concentration | 19.8% |
| Interest Coverage Ratio | N/A |
| Debt-to-Equity Ratio | 0.29 |
| Cash Coverage of Near-Term Debt | 2.05x |
Recent SEC Filings
Material disclosures from Merck &'s most recent EDGAR filings. 8-K item labels indicate the type of event reported.
| Date | Form | Details |
|---|---|---|
| 2026-05-04 | 10-Q | Quarterly report |
| 2026-04-30 | 8-K | Earnings Results |
| 2026-04-08 | DEFA14A | Additional proxy materials |
| 2026-04-08 | DEF 14A | Proxy statement |
| 2026-02-24 | 10-K | Annual report |
| 2026-02-03 | 8-K | Earnings Results |
| 2025-12-04 | 8-K | Other Events |
| 2025-12-03 | 424B5 | Prospectus supplement — possible debt or equity issuance |
Related Companies
Data Source:
Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports).
Fiscal period end: 2026-03-31.
Filing date: 2026-05-04.
Data last fetched: 2026-05-10.
Maturity schedules reflect the company's most recently reported debt repayment obligations.
Data quality: Partial.
View SEC EDGAR filings for Merck & →